Giuseppe Viglietto is a Full Professor of general pathology at the Department of Experimental and Clinical Medicine of the University Magna Græcia, Catanzaro, Italy. He graduated from the University Federico II of Naples (Italy) and specialized in genetics at the La Sapienza University of Rome. After a 3-year postdoc position at the Institute of Genetics and Biophysics in Naples, where he contributed to the cloning and the characterization of the genes encoding the enzyme G6PD and of the endothelial growth factor PlGF, he joined the National Cancer Institute in Naples as a Staff Scientist in 1992 and studied the deregulation of the cyclin-dependent kinase inhibitor p27 in human cancer. In 2001, he moved to the Institute of Experimental Endocrinology and Oncology in Naples where he started to investigate the role of PI3K/AKT pathway in cancer. In this field, Viglietto’s studies have contributed to develop the emerging concept that the localization of CDK inhibitors p21 and p27 is regulated by phosphorylation and that AKT-dependent delocalization of these inhibitors contributes to the onset/progression of cancer. Since 2004, Viglietto has been at the University Magna Græcia and since the end of 2007 he has been the PI of the Laboratory of Molecular Oncology at the Institute for Genetic Research in Ariano Irpino (AV), Italy, where his research is focused on the development of mouse models of genetic alterations detected in human carcinomas. Viglietto (cited in the list of the 2300 Top Italian Scientists of the VIA-Academy (www.via-academy.org) (4200 citations, H-index= 41, total IF=500, average IF=5,6)) has published on the most important biomedical journals of the world, in the field of human genetics (EMBOJ, PNAS, and American Journal of Human Genetics) and of molecular oncology (Oncogene, Cancer Research, JCI, Nature Medicine, and American Journal of Pathology).
Biography Updated on 13 September 2011